The Impact of Intravitreal Ranibizumab Combined with 810 nm Laser on Retinopathy of Prematurity in Zone Ⅱ Premature Infants
Objective To investigate the effect of intravitreal ranibizumab combined with 810 nm laser on the control rate of retinopathy of prematurity(ROP)in zone Ⅱ premature infants and the level of serum vascular endothelial growth factor(VEGF).Methods A retrospective analysis was conducted on clinical data of 50 cases(90 eyes)of zone Ⅱ ROP infants admitted to Henan Children's Hospital from January 2020 to June 2023.According to the treatment plan,the infants were divided into a control group(25 cases,46 eyes)and a combination group(25 cases,44 eyes).The control group received intravitreal ranibizumab treatment,while the combination group received intravitreal ranibizumab combined with 810 nm laser photocoagulation treatment.The control rates of lesions,retinal development functional indicators[full-field electroretinogram(FERG)amplitude of the b-wave in light and dark adaptation],fluorescein fundus angiography(FFA)findings before and 1 month after treatment,and serum VEGF levels were compared between the two groups.Results The lesion control rate in the combination group(93.18%)was higher than that in the control group(78.26%),with a statistically significant difference(P＜0.05).One month after treatment,the combination group showed higher rates of reduction in fluorescein leakage,regression of neovascularization,and improvement in retinal vessel tortuosity compared to the control group,with statistically significant differences(P＜0.05).Six months after treatment,the combination group had higher FERG b-wave amplitudes in light and dark adaptation than the control group,with statistically significant differences(P＜0.05).One month after treatment,the serum VEGF level in the combination group was lower than that in the control group,with a statistically significant difference(P＜0.05).Conclusion Intravitreal ranibizumab combined with 810 nm laser photocoagulation treatment can effectively promote the improvement of FFA manifestations and retinal development function in zone Ⅱ ROP infants,inhibit VEGF expression,and increase the lesion control rate.
retinopathy of prematurityranibizumab810 nm laserdisease control rate
国家科技期刊平台
NSTL
万方数据
维普
